The production of recombinant proteins in seeds is achieved by driving transgene expression using promoters and protein targeting sequences derived from genes encoding abundant seed storage proteins. This approach is advantageous because high yields, stability and containment are conferred by the accumulation of recombinant proteins in specialized storage compartments such as protein bodies and protein storage vacuoles. Seeds are particularly suitable for the production of pharmaceutical proteins in developing country settings because they reduce the costs of production and distribution by avoiding the need for fermenter-based production capacity and a cold chain for storage and distribution, thus increasing access to critical medicines for the poor in rural areas. Seeds are also ideal for the production of oral vaccine antigens, because encapsulation within the seed provides protection that prolongs exposure to the gastric immune system and thus increases the potency of the immune response. In this review we discuss the current state of the art in seed-based molecular pharming and the future potential of production platforms based on seeds.
SEED-BASED PRODUCTION PLATFORMS: 1.The Advantages of Seeds for the Production of Recombinant Proteins
Many different plant-based systems have been described for the production of pharmaceutical proteins, often using leaf biomass, fruits, tubers, or specialized aquatic plants or cultured plant cells [1] , [2] , [3] . Seeds provide further advantages over these systems because they accumulate large amounts of protein in a relatively small volume and provide a stable environment that promotes protein accumulation and inhibits degradation, thus facilitating longterm storage [1] , [4] . For example, antibodies accumulate at high levels in seeds and remain stable for several years with no loss of activity when stored at ambient temperatures [5] . In practical terms, this means that cereal seeds containing pharmaceutical proteins can be stored and distributed in countries lacking a reliable cold chain. A relatively high protein concentration is achieved because most seeds are small and compact with a simple proteome, which also reduces the number of competing proteins released during processing. Seeds also tend to lack compounds such as phenolics and alkaloids, which are often present in leaves and which interfere with downstream processing by fouling membranes and chromatography media [6] . The specialized organelles in seeds provide further advantages such as increased stability and capacity for accumulation, bioencapsulation and containment, and enhanced processing strategies such as the use of the oil bodies found specifically in oilseeds (e.g. safflower and rapeseed) for economic purification [6] .
Seed-based production systems can be scaled up and down rapidly in response to market demand simply by adjusting the amount of land used for a specific pharmaceutical crop. Field plants can be scaled up between 100-fold and 1000-fold in a single season depending on the species [7] and plant lines can be stored indefinitely and in an easily accessible form simply by storing seeds [2] .
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for the development of oral vaccines that can be administered as flakes or flour with minimal purification [8] .
The Challenges of Seed Based Systems

Product Quantity and Quality
In order to determine whether any production system is economically viable there are two major critical factors: the amount of product that accumulates per unit biomass (productivity, specific yield) and the quality of the final product in terms of homogeneity and functionality. The accumulation of pharmaceutical proteins in seeds can be enhanced in several ways, e.g. by using promoters derived from the genes encoding abundant seed storage proteins [9] , the optimization of codon usage, the use of a KDEL tag to retain proteins in storage compartments derived from the secretory pathway, and the use of other targeting signals derived from storage proteins [10] . The restriction of recombinant proteins to seeds and the control of protein targeting within seeds increases product homogeneity and therefore the overall quality of protein batches produced in seeds.
Purification
More than 80% of the total production costs of a recombinant protein are associated with downstream processing, which tend to be similar across platforms thus reducing the comparative economic advantages of upstream production using plants [11] . Strategies to reduce the downstream production costs of plant-based systems have therefore received considerable attention, and the limited number of competing molecules (proteins and small-molecule metabolites) in seeds means that separation and extraction strategies that purify the recombinant protein are simpler to implement [12] . The development of purification strategies based on oleosin fusions in oil bodies or polymer fusions in other compartments provides a convenient method for the isolation of even recalcitrant proteins [13] . [23] . Typical seed crops used for molecular pharming include the cereals rice [5] , wheat [5] , barley [24] and maize [25] , the legumes pea [26] , cowpea and soybean [27] , tobacco [28] , [29] , Arabidopsis [30] and the oil crops canola and safflower [31] .
Maize seeds are the most widely used platform and have been developed commercially in several independent ventures both for pharmaceutical products and industrial proteins . Highlights include the production of the heat-labile enterotoxin B subunit (LTB) as an early example of an oral vaccine candidate [32] , the spike protein N-terminal domain from Transmissible gastroenteritis coronavirus (TGEV), which was one of the first plant-derived oral vaccines to be tested in animals [35] , HIV-neutralizing antibody 2G12 with homogeneous glycans, providing an inexpensive source of a microbicide to prevent the spread of HIV/AIDS [43] , [44] , gastric lipase, one of the first plant-derived pharmaceuticals in clinical development [47] , and -glucuronidase, which was commercially released as a laboratory reagent [49] . Rice seeds have also been widely used [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] , particularly for the production of dietary proteins such as lactoferrin [56] , [57] lysozyme [57] , [58] , and pollen antigens such as Japanese cedar pollen Cryj1 and Cryj2 [60] and a mite allergen [70] .
Whereas tobacco seeds have been used for a small number of experimental products usually on the laboratory scale [72] [73] [74] [75] [76] [77] [78] [79] , cowpea seeds have been extensively used for the production of multivalent vaccine antigen candidates often in combination with Cowpea mosaic virus structural proteins subunits [80] [81] [82] . Soybean seeds [83] [84] [85] [86] have also been used to produce primarily vaccine candidates, including the heat-labile enterotoxin B subunit (LTB) vaccine [83] , a nucleocapsid protein from Porcine reproductive and respiratory syndrome virus (PRRSV) [85] , and full length humanized IgG recognizing herpes simplex virus 2 (HSV-2) [27] . Like tobacco, Arabidopsis seeds have been used for mainly experimental products [87] [88] [89] [90] [91] [92] [93] [94] , whereas wheat has been pioneered not only for the production of antibodies, but also heterologous seed storage proteins and the nutrient enhancer phytase [54, 95, 96] . Safflower seeds have been used to produce apolipoprotein [97] , hirudin [98] and human insulin [99] and have been developed as an alternative to canola/rapeseed [87] , [99] . Pea seeds have been used for the experimental production of bean alpha-amylase inhibitor [100] and carcinoembryonic antigen scFv (CEA) [54] . Barley seeds have been used to produce the human growth factor Flt3 ligand [101] , collagen [22] , HIV-neutralizing antibodies [24] and human lactoferrin [102] .
An exhaustive list of molecules produced in seeds for molecular pharming applications is given in Table 1 .
PLANT SPECIES THAT PROVIDE SEED-BASED PRO-DUCTION PLATFORMS FOR MOLECULAR PHARMING APPLICATIONS
Arabidopsis thaliana
Arabidopsis seeds have been used as a production system for recombinant proteins but for experimental purposes rather than commercial exploitation because Arabidopsis seeds are tiny and the biomass is low [103] [104] [105] [106] . The advantage of Arabidopsis is its amenability to transformation and regeneration, the short generation cycle and the production of thousands of seeds, which means it can be used to test the efficiency of molecular pharming strategies ahead of deployment in more expensive species [103] .
Tobacco
Tobacco has a long history as both a model system and as a commercial platform for molecular pharming, which makes it the most widely used species for the production of recombinant pharmaceutical proteins in the research laboratory and commercially, but platforms based on tobacco are typically based on leaves or cultured cells [3] [4] [5] . Although some recombinant proteins have been produced in tobacco seeds for experimental purposes (e.g. to investigate differences in protein targeting between leafy plants and cereals) the morphology of tobacco seeds is somewhat similar to those of Arabidopsis plants, with the same disadvantages in terms of size and biomass.
Cereals
Cereal seeds naturally accumulate large amounts of protein in the endosperm, which has evolved to store proteins and other macromolecules for consumption during germination. By subverting the natural protein storage mechanisms, cereal endosperm tissue therefore provides an ideal biochemical environment for the accumulation of recombinant proteins, and this is generally achieved by the formation of specialized storage compartments such as protein bodies and protein storage vacuoles, which are derived from the secretory pathway [107] . Commercial development has focused on three staple cereal crops, i.e. maize, rice and barley, with maize as a clear market leader [1] , [4] , [108] . Wheat is potentially advantageous as a pharmaceutical production crop because it has a low producer price, but commercial development is hampered by its low transformation efficiency and the low yields of recombinant proteins that have been achieved [5] .
Maize
Maize has many advantages over other plant seeds which make it ideal for the production of recombinant pharmaceutical proteins [108] . Compared to other cereals, maize has a larger grain size and a higher proportion of endosperm, which can occupy up to 82% of the seed [109] . Maize plants have undergone selective breeding for both food and feed production, and have been optimized for increased seed yield. Therefore maize has a high biomass yield per hectare and lower production costs than other major cereals [110] . Unlike other cereals, the use of the C4 photosynthetic pathway in maize increases the efficiency of biomass production. On a technological level, maize benefits from relatively straightforward and efficient in vitro culture, transformation and regeneration protocols as well as a suite of seed-specific promoter systems that can be used to drive transgene expression alone or in combination. Maize was therefore used to produce the first commercially successful plantderived recombinant proteins, namely avidin and -glucuronidase marketed by ProdiGene Inc. [39] , [111] .
One potential drawback of maize is that, unlike the other cereals discussed below, it is a cross-pollinating species, which means the cultivation of pharmaceutical crops without containment can lead to gene flow into non-pharmaceutical crops [112] . Even so, this can be addressed by appropriate cultivation management practices that mitigate gene flow, and which are already widely established to prevent gene flow between GM and conventional food crops. None of the other cereal crops discussed below can presently match the yields of recombinant protein achieved in maize [4] .
Rice
Rice shares many of the advantages discussed above for maize, including the high grain yield (albeit lower than maize), the existence of straightforward in vitro cultivation and transformation procedures, and the ability to scale up production rapidly. In addition, rice is a self-pollinating species so in theory there should be a lower risk of gene flow from pharmaceutical crops to nonpharmaceutical crops and wild relatives. However, the protein content of rice seeds is lower than maize, wheat and barley and the cost of growing rice is also much higher than the other cereals [4] .
An interesting and apparently unique property of rice endosperm is the diversity of storage compartments. The endosperm cells of most cereals contain specialized storage compartments known as protein bodies, which have evolved specifically for the storage or proteins and bud from the endoplasmic reticulum when sufficient protein has accumulated [69] . These compartments can also be used to accumulate recombinant proteins expressed using Sweet brazzein Sweet-tasting protein [42] Human monoclonal antibody 2G12 Antibody [43] , [44] Hepatitis B surface antigen Detectable viral antigen [45] Nitrate reductase and peroxidase Industrial enzyme [46] Laccase Industrial enzyme [53] Cellulase Industrial enzyme [23] Gastric lipase Industrial enzyme [47] Respiratory syncytial virus (RSV), IgG( Ab form) Antibody [48] Sperm (antigen) Antigen [48] -glucuronidase Enzyme [49] Newcastle Disease virus (NDV)-poultry Antigen [50] Anti/EGFR antibody C225 Antibody [51] Aspergillus phytase + ferritin Enzyme + Protein [52] Maize Aspergillus phytase Enzyme [53] Carcinoembryonic antigen scFv (CEA) Antigen [54] Insuline-like growth factor-1 Hormone [55] Human lactoferrin Glycoprotein [56] , [57] Lysozyme Enzyme [57] , [58] Human -interferon Protein [15] Porcine epidemic diarrhea virus (PEDV) Vaccine [59] Polypeptide consisting of 7 dominant human T-cell epitopes derived from the Japanese cedar pollen allergens, Cryj1 and Cryj2 Peptide for immunotherapy [60] VP2 protein of infectious bursal disease virus (IBDV)/chicken Antigen [21] Hepatitis B virus (HBV) core particles Antigen [61] Rice Novokinin (Arg-Pro-Leu-Lys-Pro-Trp, RPLKPW) plus KDEL Hypotensive peptide [62] ( Cholera toxin B subunit Mucosal vaccine [19] Transferrin Glycoprotein [65] Herpes simplex virus Antibody [27] Provitamin A Vitamin [18] Recombinant human cytokine GM-CSF Cytokine [66] Antibody for Streptococcus mutans surface antigen I ⁄ II Antibody [67] Aspergillus niger phytase Enzyme [68] 7Crp peptide Peptide [69] Mite allergene Allergene [70] Human growth hormone Hormone [71] Glycoprotein B of human cytomegalovirus Glycoprotein [72] Human growth hormone Hormone [73] Human haemoglobin ( -and -globin) Blood substitute [17] Methionine Protein-based amino acid [74] 14D9 antibody Antibody [75] Recombinant human cytokine GM-CSF Cytokine [76] Carcinoembryonic antigen scFv (CEA) Antigen [77] Human monoclonal antibody 2G12 Antibody [78] Tobacco Tumor-targeting mAb H10 Antibody [79] Canine parvovirus VP2 epitope Vaccine antigen [80] Foot and mouth disease virus VP1 epitope Vaccine antigen [81] Human rhinovirus (type 14) VP1 epitope Vaccine antigen [82] Pseudomonas aeruginosa membrane protein F epitope Vaccine antigen [82] Mink enteritis virus VP2 epitope Vaccine antigen [82] Cowpea Staphylococcus aureus D2 epitope of fibronectin-binding protein Vaccine antigen [82] Heat-labile enterotoxin B subunit (LTB) Subunit vaccine [83] Human simplex virus Antibody [27] Human growth hormone Hormone [84] Nucleocapsid the appropriate promoters and targeting sequences, increasing protein yields by providing an ideal stable environment [113] , [114] . Most cereals form a single type of protein body, whereas rice endosperm forms two distinct types of compartment, known as PB-I and PB-II [69] . Protein bodies are insoluble in low-salt aqueous buffers, so they can be purified by centrifugation. Therefore the presence of two different protein bodies in rice potentially allows different proteins to be expressed and targeted to different compartments simultaneously, and then recovered by first separating the compartments by density centrifugation.
The US company Ventria Bioscience Inc. has developed rice as a commercial platform and has produced USDA-approved lines that express high levels of lactoferrin and lysozyme [14] , [58] , [107] , [115] [116] [117] .
Barley
Barley is advantageous because it is self-pollinating, the producer price is low, and the seed protein content is high. It is not as widely grown as maize, rice and wheat which means that genetic isolation can be achieved simply by growing the crop in an area where it is not traditionally cultivated. However, techniques for in vitro culture and transformation are not as widely established as in other cereals [4, 117] .
The Icelandic company ORF Genetics has adopted barley as their production platform because barley is not grown for food use on Iceland and therefore there is no risk of outcrossing [107] . The company has produced several pharmaceutical proteins in barley seeds, including the marketed products ISOkine™ and DERMOkine™ (human-like growth factors) which are approved for laboratory use and as cosmetic ingredients, but nevertheless demonstrate that seed-based systems can achieve GMP-like batch-to-batch reproducibility and quality [118] .
Legumes
Leguminous plants are potentially attractive production systems because their seeds have a protein content of 20-40% (compared to 10-12% in cereals) which could favor high yields of recombinant protein if the protein biosynthesis machinery is harnessed efficiently [4] . Only soybean and pea have been explored for their potential in molecular pharming applications, but the lack of straightforward in vitro culture and transformation methods for these species has hampered progress [26, 27] . Apart from a recent study where high yields of a human growth hormone (hGH) were obtained in soybean [84] , to date yields of recombinant proteins in legume seeds have been low [119] [120] [121] [122] . The higher protein content of legume seeds compared to cereals is also balanced by the lower biomass yields per hectare [4] .
Oilseed Crops
Oilseeds are so named because they contain a large amount of stored oils, which accumulate in compartments known as oil bodies that can be exploited to simplify the purification of recombinant proteins. The primary example is the oleosin fusion platform, which has been developed commercially in safflower and rapeseed by the Canadian company SemBioSys Genetics [123] , [124] . The recombinant protein is expressed as a fusion with oleosin, an endogenous protein that normally localizes within oil bodies. Therefore, the fusion protein becomes concentrated in the oil bodies, which can be separated from the bulk seed homogenate in the lipid fraction. Treatment of the lipid fraction with an endoprotease then separates the recombinant protein from its fusion partner, allowing recovery in the aqueous phase [123] , [124] .
As stated above, the olesion fusion platform has been developed primarily in rapeseed and safflower, the latter chosen for commercial development because it is self-pollinating and has a higher protein yield than rapeseed, which is an outcrossing plant. However, both oilseed crops have a lower overall biomass yield compared to cereals [4] . The anti-coagulant hirudin was produced in rapeseed by SemBioSys to demonstrate the principle of the oleosin fusion platform [97] , but commercial development has focused on human insulin produced in safflower (this completed phase I and II clinical trials in 2009) with several other products in the pipeline, although the company is currently struggling to secure further financing [125] [126] [127] .
FUTURE PROSPECTS
Seeds provide a number of clear advantages for molecular pharming, particularly the enhanced stability achieved by exploiting a natural storage organ, the large biomass yields that can be achieved using cereals seeds (particularly maize), the ease of purification and the potential to use seeds for oral administration of vaccines, but reducing the cost of downstream processing remains a significant challenge [128] . Downstream purification costs are negligible when seeds are used for oral administration because processing is reduced to simple procedures such as crushing or grinding [78] [117], [129] . Seed-based expression platforms will therefore play a prominent role in the development of future oral vaccine candidates as demonstrated most recently with Japanese cedar pollinosis vaccines [130] . However dosage will need to be monitored carefully because differences in expression levels between batches would affect the amount of ingested recombinant protein. Some form of quality control involving the testing of homogenized seed samples would be required to ensure that doses remain within a certain tolerance.
Downstream purification costs can also be reduced by using seed extracts rather than purified seed-derived proteins. This would be suitable for topical products, such as griffithsin, cyanovirin-N and HIV-neutralizing antibodies, which are envisaged for passive immunization against the spread of HIV. For such applications, the presence of additional plant proteins and metabolites would not present a significant risk because people are routinely exposed to such compounds by contact and in their food [2] , [44] , [131] , [132] . For proteins intended for injection, conventional production including extraction and purification according to GMP would still be required. As well as the economic benefits of minimal processing, the ability to use powdered seeds or seed extracts directly would solve a major current challenge in the distribution and storage of vaccines and other medicines in developing countries, namely the reliance on a cold chain [133] .
Another potential benefit of seeds is their ability to produce different recombinant proteins simultaneously, particularly by exploiting different targeting strategies and storage compartments [see Stoger et al., this issue]. One potential application of this approach is the simultaneous production of different microbicide components in a single formulation, since combination microbicides are more effective than single molecules and help to prevent the evolution of resistant pathogens [134] , [135] . The cost of producing each component separately can be prohibitive, but by engineering seeds to produce multiple proteins then the costs of single and multiple formulations would be the same. There are already many examples of transgenic seeds co-expressing different enzymes in the context of metabolic engineering [136] , [137] , [138] , so it only remains to ensure that the yields and stoichiometry of the components can be regulated productively.
Proteins that need to be purified from seeds are often expressed with affinity tags that allow them to be isolated by affinity chromatography, e.g. polyhistidine tags that can be captured by metal ions and specific epitopes such as FLAG that can be captured with their corresponding antibodies, so that generic purification processes can be used with diverse proteins [1] , [139] . However, these affinity tags must be removed before a plant-derived pharmaceutical product can be approved because they may alter its properties compared to the native protein, and this in vitro enzymatic or chemical process reduces the final product yield and introduces additional excipients that must be removed in subsequent purification steps [128] . The oleosin fusion method discussed above avoids some of these challenges by providing a facile way to isolate the (hydrophilic) native protein from the lipid fraction of the seeds following endoprotease cleavage [124] . A similar concept is exploited when proteins are expressed as fusions with an integral membrane-spanning domain derived from the human T-cell receptor, allowing protein extraction in a small volume using appropriate buffers and detergents [140] . Other separation methods have been devised that rely neither on fusions nor on chromatographic separations, e.g. the purification of recombinant collagen from low-pH maize seed extracts by cross-flow filtration, which is possible because of the distinct molecular properties of collagen compared to endogenous endosperm proteins [141] .
The many advantages provided by seed-based molecular pharming platforms will not be realized unless the general barriers to the adoption of genetically engineered crops are overcome, and these are political rather than technical [142] . Genetically engineered crops are burdened with onerous regulations that differ widely from country to country, some of which are stringent but fair, whereas others (particularly within the European Union) are irrational and unnecessarily restrictive [143] [144] [145] . The benefits of molecular pharming using seeds would be promoted by the adoption of a rational, science-based and globally harmonious regulatory framework that removes trade barriers and embraces risk/benefit awareness rather than the current precautionary approach focusing on the elimination of all risks [146] , [147] .
CONCLUSION
The advantages of seeds (and particularly cereal seeds) as a production platform for molecular pharming reflect two key properties, namely their ability to accumulate proteins in a stable environment and maintain them in an inert state (thus making cold chain infrastructure unnecessary), and their suitability for minimal processing in relation to oral and topical application routes (thus making extensive downstream processing unnecessary). Downstream processing accounts for much of the cost of drug manufacturing, whereas the need for a cold chain accounts for much of the cost of drug distribution and makes distribution next to impossible in countries where a cold chain infrastructure is unavailable. By eliminating these requirements, seeds can reduce the costs of drug manufacture and supply by over 90% and enable the distribution of drugs to remote areas without refrigeration, making them ideal for deployment in developing-country settings. Because many rural communities in developing countries rely on subsistence agriculture and have limited access to medicines, the use of staple cereals to provide such medicines could have a powerful impact on the health and wellbeing of the world's poorest people.
In the developed world, seed-based production systems still provide an economical alternative to conventional manufacturing processes, because they are much more scalable than fermenterbased platforms and the seed proteome is simple, which means that innovative purification schemes can be developed to reduce the number of chromatography steps required for purification and therefore reduce the overall costs of production. The production of recombinant pharmaceutical proteins in leafy crops has been achieved under GMP conditions, but processing requires a complex series of filtration and chromatography steps to remove the large number of endogenous plant proteins and metabolites found in leaves. Seeds offer several opportunities to remove such requirements by simplifying the processing steps, including the isolation of protein bodies and the expression of fusion proteins targeted to oil bodies, essentially performing a biological prefractionation before processing. This indicates that pharmaceutical proteins could be extracted from seeds using streamlined processes with simple steps, suggesting that even proteins intended for injection could eventually be produced inexpensively in developing country settings perhaps using portable and self-contained processing suites.
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